Drugs · acquisition-cost intelligence
JANUMET XR
sitagliptin and metformin hydrochloride· ingredient sitagliptinBiguanides· METFORMIN HYDROCHLORIDE 1000 mg/1; SITAGLIPTIN PHOSPHATE 100 mg/1; METFORMIN HYDROCHLORIDE 1000 mg/1; SITAGLIPTIN PHOSPHATE 50 mg/1; METFORMIN HYDROCHLORIDE 500 mg/1; SITAGLIPTIN PHOSPHATE 50 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$5.28
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 5 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other sitagliptin products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| ZITUVIMET XR | $5.03 | −$0.25680 |
| ZITUVIMET | $5.03 | −$0.25110 |
| JANUMET | $5.28 | −$0.00020 |
| ZITUVIO | $10.06 | +$4.77 |
| JANUVIA | $10.55 | +$5.27 |
Medicare Part D coverage · CY2026
On 316 plan formularies · typical tier 3
Prior auth 0% · Step therapy 0% · Quantity limit 93% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.